Details of the Drug Combination

General Information of Drug Combination (ID: DC05JUS)

Drug Combination Name
Amonafide Taxol
Indication
Disease Entry Status REF
Adenocarcinoma Investigative [1]
Component Drugs Amonafide   DMAH59S Taxol   DMUOT9V
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable
High-throughput Screening Result Testing Cell Line: NCIH23
Zero Interaction Potency (ZIP) Score: 3.89
Bliss Independence Score: 4.35
Loewe Additivity Score: 4.84
LHighest Single Agent (HSA) Score: 6.59

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Amonafide
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 3 [2]
Ovarian cancer 2C73 Phase 3 [2]
Prostate cancer 2C82.0 Phase 3 [2]
Indication(s) of Taxol
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [3]
Solid tumour/cancer 2A00-2F9Z Approved [4]
Pancreatic cancer 2C10 Phase 3 [5]
Gastric adenocarcinoma 2B72 Phase 2 [6]
Ovarian cancer 2C73 Phase 2 [6]
Taxol Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Apoptosis regulator Bcl-2 (BCL-2) TTJGNVC BCL2_HUMAN Modulator [3]
Tubulin beta (TUBB) TTYFKSZ NOUNIPROTAC Modulator [3]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adenocarcinoma DCXI4FL HCT-15 Investigative [1]
Adult T acute lymphoblastic leukemia DCQPDNN MOLT-4 Investigative [1]
Astrocytoma DCJ4EQ2 U251 Investigative [1]
Chronic myelogenous leukemia DCRYZ9N K-562 Investigative [1]
Lung adenocarcinoma DCA10N3 HOP-62 Investigative [1]
Colon adenocarcinoma DC59TQ3 COLO 205 Investigative [7]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DrugCom(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 ClinicalTrials.gov (NCT00715637) Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDEStudy. U.S. National Institutes of Health.
3 Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.